Treatment of Post-Obstructive Pneumonia

Initial Antibiotic Selection

The American College of Physicians recommends post-obstructive pneumonia treatment with broad-spectrum antibiotics that have mandatory anaerobic coverage, making β-lactam/β-lactamase inhibitor combinations the preferred first-line agents, with treatment stratified by severity and location of acquisition 1
For ward patients admitted from home, the optimal regimen is a β-lactam/β-lactamase inhibitor combination, such as amoxicillin-clavulanate or ampicillin-sulbactam, given orally or intravenously, as recommended by the Infectious Diseases Society of America 2, 3, 1
Alternative regimens for ward patients include clindamycin monotherapy, intravenous cephalosporin plus oral metronidazole, or moxifloxacin monotherapy, as suggested by the European Respiratory Society 2, 3
For ICU patients or nursing home admissions, the preferred combination is clindamycin plus a cephalosporin, due to the higher risk of resistant organisms and polymicrobial infection, as recommended by the Society of Critical Care Medicine 2, 3, 1

Add antipseudomonal coverage when two or more risk factors are present, including recent hospitalization, frequent antibiotic use, severe underlying lung disease, or oral steroid use, as recommended by the American Thoracic Society 2, 3
For patients requiring Pseudomonas coverage, use piperacillin-tazobactam plus either levofloxacin or an aminoglycoside, as suggested by the Infectious Diseases Society of America 1, 4

Add vancomycin or linezolid only if the patient received intravenous antibiotics within the prior 90 days or if treated in a unit where MRSA prevalence among S. aureus isolates exceeds 20%, as recommended by the Centers for Disease Control and Prevention 1
Vancomycin for MRSA pneumonia is associated with high mortality rates, and empiric MRSA coverage should be avoided in patients without specific risk factors, as suggested by the Society for Healthcare Epidemiology of America 4, 5, 1

Initiate parenteral therapy immediately in the emergency department without delay, as mortality increases with treatment delays, as recommended by the American College of Emergency Physicians 1
Switch to oral therapy when the patient is hemodynamically stable, afebrile, and clinically improving, as suggested by the Infectious Diseases Society of America 1

Obtain sputum cultures or bronchoscopic samples before initiating antibiotics whenever possible, but never delay treatment in critically ill patients, as recommended by the American Thoracic Society 1, 5
Once a pathogen is identified, narrow therapy to target that organism specifically, as suggested by the Infectious Diseases Society of America 6, 1

Monitor response using body temperature, respiratory parameters, and hemodynamic stability, as recommended by the Society of Critical Care Medicine 2, 3
Continue treatment for a minimum of 5 days and until the patient has been afebrile for 48-72 hours with no more than one sign of clinical instability, as suggested by the Infectious Diseases Society of America 1

Differentiate between early non-response and late non-response, and perform full reinvestigation and initiate a second empirical regimen using antibiotics from different classes than previously used, as recommended by the European Respiratory Society 2, 3, 5
In unstable non-responding patients, it is critical to initiate a second empirical regimen, as resistance to "in-use" antibiotics has likely developed, as suggested by the Society for Healthcare Epidemiology of America 6, 5